Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS-GCGRRx · 1 trial · 1 indication
Change from Baseline
Change from Baseline
| Arm | Type | Description |
|---|---|---|
| ISIS-GCGRRx | EXPERIMENTAL | ISIS-GCGRRx once weekly dosing for 13 weeks |
| Placebo | PLACEBO_COMPARATOR | once weekly dosing for 13 weeks |
| Name | Type | Description |
|---|---|---|
| ISIS-GCGRRx | DRUG | once weekly dosing for 13 weeks |
| Placebo | DRUG | once weekly dosing for 13 weeks |
Inclusion Criteria: * Male or female, age 18 to 75 * BMI ≥ 25.0 kg/m2 \< 36.0 kg/m2 * HbA1c ≥ 7.5% and ≤ 10.5% * Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior to screening e...
Top 20 of 31 competitors
ISIS-GCGRRx is an investigational drug being studied for the treatment of Type 2 Diabetes. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its effects on hepatic lipid and glycogen content in patients with Type 2 Diabetes.
ISIS-GCGRRx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company. Ionis Pharmaceuticals is listed on the stock exchange under the ticker symbol IONS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ISIS-GCGRRx is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for its potential use in treating Type 2 Diabetes, and its safety and efficacy have not yet been established.
ISIS-GCGRRx has one completed Phase 2 clinical trial registered under the identifier NCT02824003. This study, titled 'Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes,' was conducted in Austria with 15 participants. The trial was randomized, double-blind, and placebo-controlled.
ISIS-GCGRRx is the specific name of the investigational drug being developed by Ionis Pharmaceuticals. No alternative names for this drug have been disclosed in the available information. It is important to note that ISIS-GCGRRx is distinct from other drugs and should not be confused with them.